What the business is, and whether it's a good one at a fair price.
Develops, manufactures and sells generic pharmaceuticals globally, with operations spanning India, the US, Europe and emerging markets. Global Generics made up 85.8% of FY26 segment revenue at Rs 18,202.7 crore with a 24.0% segment EBIT margin, while Pharmaceutical Services and Active Ingredients (PSAI) contributed 14.0% at Rs 2,975.0 crore with a -3.0% segment EBIT margin. The Q1 FY27 geographic mix was North America Generics US$236M, Emerging Markets Rs 1,833 crore (+31% YoY), India Rs 1,718 crore (+17% YoY), Europe EUR 131M and PSAI US$91M. Manufacturing sits at facilities in Bachupally (biologics) and Srikakulam (FTO-SEZ), with FY27 capex guided at around Rs 1,800 crore and 27 US product launches targeted. Recent regulatory actions include USFDA approval for a rituximab biosimilar (to be commercialized in the US by Fresenius Kabi), a bosutinib first-to-file launch with 180-day exclusivity in the US, and Form 483s with 7 observations at Bachupally and 3 at Srikakulam. Q1 FY27 was hit by a Rs 240 crore semaglutide API provision and lower lenalidomide, with EBITDA margin at 12.5%; semaglutide supply is targeted to resume by November 2026. Materials accounted for 19.3% of FY26 revenue, employees 17.8% and other operating expenses 26.8%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from DR. REDDY S LABORATORIES's filed financials and exchange disclosures
DR. REDDY S LABORATORIES is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol DRREDDY.
Yes. Over the trailing twelve months DR. REDDY S LABORATORIES reported a net profit of ₹3,183 Cr on revenue of ₹33,228 Cr.
Yes. The dividend yield is 0.68% at the current price. It paid out 16% of its profit as dividend in FY26.
No. Debt stands at 0.16× equity, and it carries net debt of ₹4,757 Cr. That is lower than 47% of its 171 Pharmaceuticals peers.
On trailing P/E, DR. REDDY S LABORATORIES ranks 88 of 169 in Pharmaceuticals — cheaper than 48% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session DR. REDDY S LABORATORIES moves 0.73% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by DR. REDDY S LABORATORIES appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
